18-Jan-2012 - Medicago, Inc.

Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology

Medicago Inc.  and Cellectis plant sciences, a subsidiary of Cellectis SA announced the signing of a research agreement under which Medicago and Cellectis will collaborate to improve therapeutic proteins expressed from tobacco leaves.

"We look forward to working with Cellectis plant sciences to assess their nuclease technology for use in our ongoing work to develop biosimilar products," said Dr. Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "This tool has the potential to hasten the expansion of our platform towards the production of a wider range of therapeutic proteins including biosimilars, and complement our existing tools for the control of protein glycosylation."

Luc Mathis, CEO of Cellectis plant sciences commented, "I am very proud to see the Cellectis technology being applied for use in plants to produce potential products for human health benefit, and expect that we will see additional opportunities for our technology in the near future."

Facts, background information, dossiers
  • tobacco
More about Medicago
  • News

    Medicago to build $245M production facility in Quebec City

    Medicago announced that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago's Quebec City office and laboratories. The project is expected to generate ... more

    Medicago announces research collaboration for the development of a non-influenza vaccine candidate

    Medicago Inc. announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.Under the terms of the research collaboration, Medicago will apply its transient expression system to deve ... more

    Medicago announces an extension of its agreement with Genopole biopark

    Medicago Inc. announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense. This laborator ... more

  • Companies

    Medicago, Inc.

    Medicago is a publicly-traded biotechnology company focused on the development, production and commercialization of protein-based vaccines and biopharmaceuticals using a proprietary manufacturing system developed from its expertise in the genetic engineering of plants. more

    Medicago AB

    To be a trusted partner in the development and manufacture of critical bioreagents. To be committed to innovative solutions through excellence in research and development. To deliver highest level of quality products and world class services to our customers. To focus on broadering our rang ... more

More about Cellectis
  • News

    Cellectis’ Meganuclease Technology Used to Efficiently Prevent Viral Infection

    Cellectis  announced that scientists from Cellectis therapeutics, the French National Center For Medical Research (CNRS) and Institut de la Vision (Paris) have used its proprietary meganucleases to successfully prevent infection of cultured cells by a Herpes Simplex virus (HSV-1). The resea ... more

    Cellectis and the Center for iPS Cells Research and Application enter collaboration

    Cellectis and the Center for iPS Cells Research and Application (CiRA) of Kyoto University, Kyoto, Japan, have announced that they have started a scientific collaboration to combine Cellectis’ genome engineering technologies with CiRA’s induced pluripotent stem cell (iPS) technology to impr ... more

    Cellectis acquires assets from Cyto Pulse Sciences Inc.

    Cellectis has announced that it has acquired all the assets of Cyto Pulse Sciences Inc., a US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment. The transaction value of $2.2 million was paid in cash and closed on S ... more

  • Companies

    Cellectis SA

    Cellectis is the worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the Meganucleases and DNA recombination. The DNA ... more